Compare ResMed Inc. (RMD) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Sibanye Stillwater Ltd — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.73B), while Sibanye Stillwater Ltd trades at $13.02 (market cap $9.31B). The key difference: ResMed Inc. is far larger — about 3.4× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (6.17%). Which is the better fit depends on your goals.
| RMD | SBSW | |
|---|---|---|
Market Cap | $31.73B | $9.31B |
Sector | Health | Basic Materials |
52-Week High | $283.28 | $21.12 |
52-Week Low | $182.82 | $8.00 |
Enterprise Value | $31.08B | $10.24B |
Dividend Yield | 1.2% | 6.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.
Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.
SBSW trades at $12.90, up 0.86% with a bullish technical signal. The company shows strong operational momentum with 54% YoY revenue growth and 111% EBITDA growth in H1 2026. Valuation metrics appear attractive with P/E of 10.2 and P/S of 0.88. Analyst consensus is mixed with 43% buy ratings and $14.00 price target, while technical indicators show bullish moving averages and neutral oscillators.
The outlook suggests potential upside from current levels supported by strong H1 2026 results and disciplined capital allocation. Key risks include commodity price volatility and the company's recent history of net losses. The stock presents a turnaround opportunity with improving cash flow trends and operational efficiency gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
